RxDoctor Payments Data

Cory Stewart, MD

Family Medicine · Camillus, NYNPI 1821672379

Payments from drug & device makers

$2,928in general payments, 2019–2025

Across 90 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$369
  • Pfizer$230
  • Galderma Laboratories, L.p.$167
  • Exact Sciences$64
  • Sumitomo Pharma America, Inc.$62
  • plus $433 from 14 others

What the payments were for

  • Food & beverage$2,928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,928 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$69,404
Medicare patients
167
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$48,762
JardianceEmpagliflozin39$39,980
EliquisApixaban44$37,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$31,602
FarxigaDapagliflozin Propanediol12$15,304
XareltoRivaroxaban16$9,934
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,273
Pregabalin18$3,455
Atorvastatin Calcium242$2,229
Albuterol Sulfate HfaAlbuterol Sulfate72$1,905
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$1,513
Lisinopril171$886
Rosuvastatin Calcium72$871
Omeprazole97$869
Mirtazapine37$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$48,76242 claims
GSKTrelegy Ellipta, Anoro Ellipta$51$40,87559 claims
PfizerEliquis$230$37,90944 claims
AstraZenecaFarxiga$369$15,30412 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$62767 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Camillus

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →